Morphogenesis Successfully Completes its First-in-human Phase 1 Clinical Trial for Melanoma
Tampa, FL, August 17, 2020 – Morphogenesis, Inc., a clinical-stage biotechnology company based in Tampa, Florida, developing immunotherapies to treat patients with cancer, is excited to announce the successful completion of the Company’s first-in-human Phase 1 clinical trial for its cancer immunotherapeutic (IFx-Hu2.0).
Morphogenesis, Inc. and the USF Health Taneja College of Pharmacy Enter into an Exciting New Partnership
Tampa, FL, July 15, 2020 – Morphogenesis, Inc., a clinical-stage biotechnology company based in Tampa, Florida, developing novel immunotherapies to treat patients with cancer, is excited to announce a new partnership with the University of South Florida Health (USF Health) Taneja College of Pharmacy (TCOP).
Morphogenesis expands the use of its intralesional cancer vaccine into patients with advanced Merkel cell carcinoma or cutaneous squamous cell carcinoma
TAMPA, Fla. – (January 29, 2020) – The FDA has allowed Morphogenesis to expand its human clinical trials using its ImmuneFx (IFx) cancer vaccine technology into two more types of cancer, advanced Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).
Morphogenesis, Inc and the Cell and Gene Therapy Group at Karolinska Institutet Announce Collaboration to Develop Targeted Immunotherapies for the Treatment of Cancer
Amber Brinkley – Kippen Communications
TAMPA, Fla. – (September 11, 2018) – Morphogenesis, Inc., a Tampa, FL-based immunotherapy company, and the Cell and Gene Therapy Group, Department of Medicine, Huddinge at Karolinska Institutet (KI) today announced the commencement of a two and a half year collaboration combining Morphogenesis’ gene therapy with the exosome-mediated delivery technology developed by the KI Department of Medicine.
Morphogenesis, Inc Raises $16 Million to Advance into Human Clinical Trials
Patricia Lawman, Chief Executive Officer – Morphogenesis, Inc.
Morphogenesis, Inc., a Tampa, FL-based immunotherapy company closed a $16 million Series A investment round led by Dr. Kiran Patel and KP Biotech Group, a company managed by Dr. Kiran Patel. With the completion of the Series A Round, Dr. Kiran Patel was elected Chairman of the Board of Morphogenesis.
Morphogenesis Announces Issuance of US Patent for Cancer Vaccines under Expedited Cancer Moonshot Immunotherapy Program
TAMPA, FL – Morphogenesis, Inc., a biotechnology company focused on the development of cell and gene therapies for the treatment of cancer, today announced that the United States Patent and Trademark Office has issued US Patent 9,555,988 covering methods for treating cancer using gene therapy.
Morphogenesis Inc., host to the White House Cancer Moonshot Summit in Tampa Bay, hopes to give voice to thousands through its online event The Vice President of the United States has called together the entire cancer community—researchers, doctors scientists, philanthropists, advocates, patients and survivors for the Cancer Moonshot Summit on June 29, 2016. The goal of the Cancer Moonshot Summit is to double the rate of progress in cancer prevention, diagnosis, treatment and care over the next five years and to ultimately end cancer as we know it. Morphogenesis, Inc. will host one of hundreds of summits around the country in conjunction with the Cancer Moonshot Summit held in Washington, DC. Read More
April 20, 2016
TWO TAMPA INSTITUTIONS JOIN FORCES TO COMBAT ONE OF FLORIDA’S BIGGEST HEALTH CHALLENGES Moffitt Cancer Center and Morphogenesis team up to test new melanoma therapy Morphogenesis, Inc., a research and development company, announced today it is partnering with Moffitt Cancer Center to test an innovative new way to treat one of Florida’s biggest health challenges – melanoma. Florida ranks second, behind California, in the number of new cases of melanoma each year. It was estimated by the American Cancer Society that in 2015, 5,480 new cases of melanoma would be diagnosed in the State. Read More
10500 University Center Drive
Tampa, FL 33612
Phone: (813) 875-6600
Fax: (813) 631-1980